Background:-Osteoporosis is an important cause of morbidity in patients with β-thalassemia. The pathogenesis of reduced bone mineral density (BMD) is multifactorial. A range of genetics factors have been implicated in patients with osteoporosis. Polymorphism at the Sp1 binding site of the collagen type I A 1(COLIA1) gene is thought to be an important factor in development of osteoporosis. Objective:-is to study the relationship between SP1 polymorphism in the collagen type 1 alpha 1 gene and the development of osteoporosis in patients with Beta thalassemia. Methods:-A total of 40 patients with β-thalassemia(21 females &19 males)aged 6-18 yearsand 40 healthy subjects cross matched with age and sex. Serum osteocalcin, serum alkaline phosphatase, calcium and DEXA were examined in all patients. The COLIA1 Sp1genotypes (SS, Ss, ss) were measured by digestion using restriction enzyme (Bal1) of DNA amplified by the polymerase chain reaction (PCR). Results:-SS (G/G) genotype in β-thalassemia major was30.7% and in β-thalassemia intermedia was 49.4% and the Ss (G/T) genotype in βT Major was 55.63% and in βT intermedia was 50.6%, the ss genotype (T/T) type in βTM was 13.67% only. The difference was statistically significant (p= 0.040). There was highly significant difference between thalassemia major and thalassemia intermedia compared to control group as regard Ca, OC, ALP and DEXA (P= 0.000). Conclusions:-Detection base substitutions at the Sp1 binding site on the COLIA1 gene in early years considering an important role in preventing osteoporosis in children with beta -thalassemia.and early mangment of these patients.
INTRODUCTION
eta thalassemia syndromes are a group of genetic diseasesfamous by a genetic defect in the formation of β-globin chains. This genetic deficiency leads to marked transfusiondependent anemia in the homozygous type of beta thalassemia (thalassemia major) while in the heterozygous type of the β-thalassemia (thalassemia minor) leads to mild to moderate microcytic anemia. Patients with clinical severity of the disease lie between thalassemia major and thalassemia minor are defined as thalassemia intermedia. Many different genotypes are associated with thalassemia intermedia [1] .
In spite of the improved treatment of the hematologic disorder and its complications, β-thalassemia patients exhibit an unbalance in bone mineral turnover with increased resorptive rates and suppression of osteoblast activity, resulting in diminished bone mineral density (BMD) more evident in the lumbar spine [2] .
Osteoporosis is a debilitating bone disease which detected by a decrease low bone mass In low bone mass, together environmental and polygenic factors are the cause of osteoporosis [3] . Many researches detected that the collagen one gene genotype diagnoses bone fracture by ways that are partly not dependent of bone mineral density [4] . There is high risk fracture in relation to SP1 polymorphism although of mild relation with bone mineral density [5] .
Polygenic factors has an important role in the development of osteoporosis, containing variability in many genes for example collagen type I alpha 1 (COLIAI), vitamin D receptors, estrogen receptors and interleukin-6 (IL-6) which monitor bone mineral density and bone shape and structure [6] .
Collagen type I considers the main component of the bone matrix. Sp1 binding site Polymorphism in the transcriptional control region of the COL1A1 gene causes alleles with a G-base at the Sp1 binding are defined as 'S', while alleles with a T-base are defined as 's'. Many studies have shown that patients with 's' allele are mostly have reduced BMD and osteoporotic fractures in several populations [7] .
The aim of this work was to study the relationship between SP1 polymorphism in the collagen type 1 alpha 1 gene and the development of osteoporosis in patients with Beta thalassemia.
SUBJECTS AND METHODS Study design and sample selection:
This study was conducted in the Outpatient Clinic of Hematology Unit of Pediatric Department and Clinical Pathology Department at Zagazig University Hospitals on 40 thalassemic patients at their regular followup visits and forty age-and sex-matched healthy children as a control group. This study included 80 subjects, They were classified as the following:
Group 1: This group included 40 patients (21 females &19 males) on follow up of β-thalassemia and they are undergoing blood transfusion and iron chelation therapy(desferal) which their ages ranged from 6-18 years and classified as: Group 1A: 22 patients with β-thalassemia major (TM). Group 1B:18 patients with β-thalassemia intermedia (TI).
Group 2:
This group included 40 apparently healthy subjects cross matched with age and sex.
An informed written consent of participation in the study was signed by the parents or legal guardians of the studied subjects. This study was approved by the Ethical Research Committee , Faculty of medicine , Zagazig University.
Each member of this research was admitted to complete history talking and full clinical observation and laboratory investigation as complete blood count done by sysmex XN, Hb electrophoresis done by full automated capillary electrophoresis, Serum Calcium level, alkalin phosphatase done by Cobas 8000, Bone Density by DEXA, Serum osteocalcine level and COLIAI gene polymorphism by using polymerase chain reaction -restriction fragment length polymorphism technique (PCR-RFLP).
-Bone Density by DEXA: Bone mineral density (BMD) of the lumber spine (second, third and fourth lumber vertebrae) was measured by dual energy X-ray absorptiometry (DEXA). All children were scanned in the supine position, BMD data were expressed as grams per centimeter. Squared and were compared with BMD values of normal children of the same age.
WHO measurement of osteoporosis using BMD measurement at the spine, hip or forearm: Normal BMD is within 1 SD of a young normal adult (T-score at -1.0 and above) Low Bone Mass (Osteopenia) BMD is between 1.0 and 2.5 SD below that of a young normal adult (T-score between -1.0 and -2.5) Osteoporosis BMD is 2.5 SD or more below that of a young normal adult (T-score at or below -2.5) Severe/Established Osteoporosis BMD is 2.5 SD or more below that of a young normal adult (T-score at or below -2. Detection of amplified PCR product by agarose gel electrophoresis: 5 μl of each sample were slowly loaded into sample well and 5 μl PCR marker was also loaded into one of the wells.
The power supply was programmed as 150 volts and 100 milli amperes for 20 minutes (Consort E 844). Then The gel was placed on the filter area of the ultraviolet transilluminator (Biometra). The amplified PCR product gave rise to 264 bp fragment.
Restriction digest reaction:
The amplified DNA was digested by using (Bal 1)(BioLabs, UAS, part No. R0534S, 250 Units) (5,000 units/ml). 10 μl of amplified product added to 16μl sterile distilled water then add 2μl of restriction enzyme and 2μl of reaction buffer then incubated at 37°C.
Detection of the band of polymorphism:
Then the digested segments were subjected to electrophoresis on eight percent non denaturing polyacrylamide gel; then the gel stained using ethidium bromide (one mg/ml) for thirty minutes at room temperature then followed by visualization by the ultraviolet (UV) transilluminator. The mplified product 264 bp fragment with Bal 1 restriction enzyme gave rise to:  Undigested 264bp fragment indicated the presence of S allele and identified as G-T substitution  Appearance of 246bp fragment indicated the presence of s allele. Thehomozygous variant SS (G/G) result in one fragment at 264 bp, homozygous variant ss (T/T) result in one fragment at 246bp while the heterozygous variant Ss (G/T) result in two fragments at 264 bp and 246 bp. described in Fig. 1 . Comparing two independent groups using Mann-Whitney test (U). For comparing between independent proportions using Chi squared test (χ 2 ) and for non-parametric data using kruskal wallis test (K). P value < 0.05 was considered statistically significant. This table shows no significant difference between cases and controls as regard age (p=0.255) and sex (p=1.000).And highly significant difference in family history (p=0.000). • p< 0.05 is significant.
RESULTS
• Sig.: Significance.
• OC: Osteocalcin.
• ALP: Alkaline phosphatase. This table showed highly significant difference between thalassemia major and thalassemia intermedia compared to control group as regard Ca, OC and ALP (P= 0.000). This table showed significant difference between thalassemia major and intermedia as regard DEXA finding concerning BMD and Z-score. Our result has been analyzed to detect the relationship between SP1 polymorphism in the collagen type 1 alpha 1 gene and the development of osteoporosis in patients with β-thalassemia The present study detected significant variation betweenTM,TI groups as regards frequency of blood transfusion and duration of iron chelation (p < 0.05) although it thought that absence significant variation between them as regard onset of blood transfusion.
Our data showed significant hypocalcaemia which was 100% in TM and 55.5% in TI compared to control group 25%.
In agreement with our data that reported biochemical hypocalcaemia in beta thalassemia patients [12] , [13] , [26] , [15] , [16] .
In contrast, there was no difference in plasma level of calcium in thalassemic patients compared with healthy control subjects [17] . Our result showed the low level of serum osteocalcin and high alkaline phosphatase in beta thalassemic patients than healthy control. Although there is absence significant variations between TM, TI as regard calcium, osteocalcine and alkaline phosphatase (p<0.05).
Low level of serum osteocalcin and high alkaline phosphatase in thalassemic patients were observed in several studies [18] , [19] , [17] , [14] , [20] .
In contrast with current study, there was no statistically significant variations in alkaline phosphatase levelsofblood transfusion dependent TMcases [21] .
In the present study, there was significantly lower BMD and Z-score values in patient groups than controls both at the lumbar and femoral levels (p<0.001) which is highly significant. Alsoit found significant variations between TM, TI (p value less than 0.05).
Several previous studies showed lower BMD in thalassemic patients [22] , [23] , [24] , [25] , [26] which due to their low physical improvement which affected by iron overload and iron chelation that can affect the liver and the endocrine system.
In contrary to our result, Christoforidis et al. [27] reported that BMD Z-scores were within normal.
In the present study, the SS genotype (G/G) in βTM, βTIand control was 30.7%, 49.4%, 79.5% respectively. The Ss genotype (G/T) in βTM, βTI and control was 55.63%, 50.6%, 20.5% respectively. The ss genotype (T/T) in βTM was 13.67% only. The difference was statistically significant (p= 0.012).Identifying the frequency of alleles inβ-thalassemia persons and health persons, it was found that the s allele higher in the TM (13.7%) than TI and control. The low percentage of ss genotype in thalassemic personsmaydue to the limited size ofthe examined group or caused by ethnic cause.It was found absenceof significant variation between TM, TI inCOLIAI genotype (p>0.05). Singh et al. [7] reported in his study that SP1 polymorphism in β-thalassemia, 19% of β -TM patients have SS (G/G) genotype, 40% have Ss (G/T) and 43% have ss (T/T).And Kritanjali et al. [13] 19.8% SS (G/G), 35.8% Ss (G/T) and 43.4% ss (T/T) with 37.7% S, 61.3 % s allelic frequencies in TM persons. Galal et al. [6] reported that80.6% of the β -thalassemia patients were homozygous for SS (G/G) and 19.4% were heterozygotes for Ss (G/T) polymorphism. Guzeloglu et al. [28] revealed that there was no ss genotype. There was Ss, SS and ss genotypes in 24.3% , 40.5% and 35.2% of patients, and in 16%, 84% of the control group, respectively. Also Arisal et al.
[9] detected that 64.3% Ss (G/T) and 35.7% SS (G/G) in β -TM. 60% Ss (G/T) and 40% SS (G/G) in β -TI which was significantly higher compared to control group (p=0.029). In a study done by Perrota et al. [29] , the genotypes of Ss and ss were accompanied by low bone mineral density than SS genotype. The absent relation between bone mineral density and COLIAI polymorphism in thalassemic persons due to low frequency of the s allele, also the low sample size. And BMD is to be detected by a manypolygenic and acquired factors, and its inheritance is due to be under polygenic effect [30] . Jin-Ai et al. [31] reported that collagen gene one alpha one genotype diagnosebone fracture by techniquesthat are partly nondependent of bone mineral density and revealed high risk of osteopenic fracture in relation to SP1 transcription factor polymorphism although of mild relation with bone mineral density. There was a study revealed absent correlation between SP1/BMD in TM patients had low bone mass [32] . Limitations of the study were that a small number of thalassemic patients were evaluated. CONCLUSION The frequency of low Bone Mineral Density (BMD) and osteoporosis are high among the children with β-Thalassemia and SP1 mutation is one of the factors that influences bone density in these patients with no significant difference between thalassemia major and intermedia. The findingsincrease the rolewhich genotyping at SP1 site may consider an important cause for detecting the thalassemic persons with a risk of achieve osteoporosis and bone fractures thataccount a possible role for improvement of osteoporosis management in those thalassemic persons. 
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